(Q43670632)

English

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kipnes MS

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Krosnick A

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Rendell MS

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Egan JW

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Mathisen AL

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Schneider RL

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

10-17

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Mechanisms and clinical effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

New drug overview. Pioglitazone hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Management of dyslipidemia in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Plasma lipids and diabetes mellitus in an adult community

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900713-6

7 January 2021

Identifiers

10.1016/S0002-9343(01)00713-6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43670632&oldid=2102412111"